SOURCE-LINKED INTELLIGENCE

Disruptive and high accuracy test for early colorectal cancer detection in blood

CORDIS · observation · Publication date unknown

E Phase 2 with €2.8M. AMADIX has identified new promising biomarkers to be incorporated to the initial signature, to improve the diagnostic performance. AMADIX has taken advantage of the potential of Artificial Intelligence and Big Data to identify CRC risk factors from the patients’ clinical records and develop diagnostic prediction models. Our goal is to validate this new signature, PreveCol, more accurate than the initial combination, based on different types of biomarkers, followed by its commercialization as LDT and as IVD kit. In addition, a risk factors-based algorithm will be incorporated, enabling to predict and identify individuals with a high risk of developing CRC or premalignant polyps, even if they are younger than 50 years old, improving their survival consequently. AMADIX expects to reach between 2023-2032 accumulated revenues of €1,997M from the commercialization of PreveCol in Europe and USA. Colorectal cancer,algorithm,artificial intelligence,life expectancy,healthcare,cancer,biotechnology,molecular biology,big data

Read original source ↗ Open in workspace

recordType

award

status

CLOSED

region

EU

value

2497568

unit

EUR